Blueprint Medicines Corp.

NASDAQ: BPMC
$44.07
-$1.78 (-3.9%)
Closing price February 8, 2023
Tuesday’s top analyst upgrades and downgrades included Boeing, Boston Scientific, ChargePoint, Deere, Foot Locker, Horizon Therapeutics, Nu, Ross Stores, Salesforce, United Parcel Service, VF,...
Wells Fargo issues a few calls and warns investors that these stocks could underperform the markets, even considering the bear market we are in now.
Monday's top analyst upgrades and downgrades included Docusign, Electronic Arts, Enterprise Products Partners, GoodRx, Netflix, Spirit Airlines, Take-Two Interactive Software, Target, Tesla and...
Wednesday’s additional top analyst upgrades and downgrades were on Danaher, eBay, GoodRx, Infosys, Valero Energy, Xylem and more.
Thursday afternoon's top analyst upgrades and downgrades included Autodesk, Check Point Software, DoorDash, Hilton, Nvidia, Upstart and more.
Wednesday's top analyst upgrades and downgrades included Apple, Applied Materials, BP, Bumble, Carrier, Harley-Davidson, Hess, Illumina, Johnson Controls and Lennar.
Monday's top analyst upgrades and downgrades included AbbVie, Alibaba, Archer Daniels Midland, Best Buy, Intel, Nikola, Peloton Interactive, SAP, Under Armour and Wynn Resorts.
Blueprint Medicines announced early on Tuesday that it had entered into a global collaboration with pharmaceutical giant Roche in which it may receive up to $1.7 billion.
Tuesday's top analyst calls included Advanced Micro Devices, Alcoa, Biomarin Pharmaceutical, Coca-Cola, Ford, General Motors, Intel, Kinder Morgan, Micron Technology, Nvidia, Tesla, Twitter and...